Skip to content

Deep Breathing Relaxation and Lemongrass Aromatherapy on Pain

Active, not recruitingNot applicableNCT07825974
View the official record on ClinicalTrials.gov

Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.

This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.

Brief summary (from the registry)

This randomized controlled trial aims to evaluate the effect of deep breathing relaxation combined with lemongrass aromatherapy on pain during arteriovenous fistula needle insertion and anxiety in hemodialysis patients. Participants will be randomly assigned to receive either the combined relaxation intervention or standard care. Pain intensity and anxiety levels will be assessed before and after needle insertion.

Study details

Official title
Effect of Deep Breathing Relaxation and Lemongrass Aromatherapy on Pain During Needle Insertion and Anxiety in Hemodialysis Patients
Conditions
  • Chronic Kidney Disease
  • End-Stage Renal Disease
  • Hemodialysis
  • Pain
  • Anxiety
Interventions
  • Behavioral: Deep Breathing Relaxation
  • Other: Lemongrass Aromatherapy
Sponsor
University of Baghdad
Start date
2026-08-11
Primary completion
2026-10-11
Sex
All
Age range
from 20 Years to 60 Years
Results posted
No results posted in this snapshot
Countries
Iraq
Total sites listed
1

Eligibility criteria

Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * receiving hemodialysis three times per week for at least 3 months; stable arteriovenous fistula or graft access; baseline pain score ≥4 on the Visual Analog Scale (VAS) during previous cannulation; ability to understand and perform breathing exercises; and willingness to participate. Exclusion Criteria: * (1)known allergy to lemongrass or essential oils; (2) history of asthma or severe respiratory disease; (3) cognitive impairment or psychiatric disorders; (4) use of analgesic or anxiolytic medications within 24 hours prior to intervention; (5) active infection or skin lesions at the access site; and (6) pregnancy or lactation

Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07825974